No Data
No Data
Sector Update: Health Care Stocks Rise Premarket Tuesday
Nanobiotix Doses First Patient in Phase 2 Study of Lung Cancer Therapy
Nanobiotix Begins Phase 2 Trial for Innovative Cancer Treatment in Stage 3 Lung Cancer
NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
Express News | Nanobiotix SA : Jefferies Cuts Target Price to $8.3 From $10.6
NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development With Next Nanotherapeutic Platform on 19 December 2024